The findings of these previous studies and the current data strongly suggest that 5‐ALA/SFC has the potential to prevent CsA‐induced nephrotoxicity/nephropathy, although further research on the molecular mechanisms underpinning the cytoprotective effects of the 5‐ALA/SFC‐HO‐1/Nrf2 axis against CsA‐induced nephrotoxicity is needed before 5‐ALA/SFC can be used clinically for the treatment of CsA‐induced nephrotoxicity. The gene discussed is HMOX1; the disease is kidney disorder.